Jane Street’s Neuropace NPCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$547K Buy
34,438
+6,346
+23% +$102K ﹤0.01% 7798
2026
Q1
$369K Sell
28,092
-89,466
-76% -$1.34M ﹤0.01% 8756
2025
Q4
$1.82M Buy
+117,558
New +$1.57M ﹤0.01% 4989
2025
Q1
Sell
-100,095
Closed -$1.12M 10238
2024
Q4
$1.12M Buy
+100,095
New +$870K ﹤0.01% 5155
2024
Q2
Sell
-72,013
Closed -$951K 9932
2024
Q1
$951K Buy
72,013
+35,191
+96% +$502K ﹤0.01% 5513
2023
Q4
$380K Buy
+36,822
New +$294K ﹤0.01% 7258
2021
Q3
Sell
-9,037
Closed -$215K 10472
2021
Q2
$215K Buy
+9,037
New +$210K ﹤0.01% 8700

Other funds holding NPCE

Jane Street's NPCE Position: Q2 2026 in Review

Jane Street increased its Neuropace (NPCE) stake by 23% in Q2 2026, buying an estimated $102K and bringing the position to 34,438 shares worth $547K. The position accounts for ﹤0.01% of the portfolio, ranked #7798.

Jane Street first reported a position in NPCE in Q2 2021 and has held it in 7 quarters since. The position peaked at $1.82M in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Jane Street held 34,438 shares of Neuropace worth $547K as of Q2 2026.
  • Jane Street bought 6,346 Neuropace shares in Q2 2026, an estimated $102K.
  • Neuropace made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #7798 holding.
  • Jane Street first reported a position in Neuropace in Q2 2021 and has held it in 7 quarters since.
  • Jane Street's Neuropace position peaked at $1.82M in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.